Mednet Logo
SpecialtiesNeurology
Neurology

Neurology

Expert perspectives on neurological conditions, stroke management, movement disorders, and neuromuscular disease.

Recent Discussions

How do you counsel B cell-depleted multiple sclerosis patients on the benefits of regular COVID-19 vaccinations?

4 Answers

Mednet Member
Mednet Member
Neurology · University of Ottawa

The fact that B cell-depleted patients render a blunted antibody response is not unexpected, but antibodies do not protect from viral infections - cells do. To measure a proper vaccine response, one wants to test T cells from patients to see if they are able to kill viral infected cells. This is wha...

What primary and secondary stroke prevention strategies do you use for patients with a pulmonary AVM (PAVM)?

1 Answers

Mednet Member
Mednet Member
Neurology · University of Calgary

This is not a common problem in stroke neurology. I have been involved in this problem for a patient with HHT (also known as Osler-Weber-Rendu syndrome). Sporadic or post-surgical AVMs may also arise but they are uncommon. In general, the treatment in both scenarios (primary and secondary prevention...

When would you start antiepileptic drugs in a critically ill patient who develops myoclonic jerks but has not yet had an EEG?

3
2 Answers

Mednet Member
Mednet Member
Neurology · Stanford Health Care Stroke Center

Treatment depends on the setting in which these myoclonic jerks are seen. In a non-cardiac arrest patient, such myoclonic jerks are often due to medications, organ dysfunction (e.g., uremia, etc), electrolyte imbalance, or non-convulsive seizures, etc, and workup for this is recommended with labs, h...

When would you consider GLP-1 receptor agonists for IIH in patients at a healthy weight and BMI?

2 Answers

Mednet Member
Mednet Member
Neurology · The University of Iowa

Randomized clinical trial data demonstrate that exenatide (exendin-4), a GLP-1 receptor agonist, reduces ICP in women with active IIH, with reductions of approximately 5–6 cm water of CSF and no serious side effects; this result is both statistically and clinically significant. This pressure-lowerin...

How do you approach treatment of 1p19q non-codeleted high grade gliomas?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Florida International University

The question focuses on the management of 1p19q non-codeleted high-grade gliomas, which for all practical purposes translates roughly to the entity that by legacy terminology has been referred to as anaplastic astrocytoma. This question has come into focus with the recent publication of results of t...

When would you consider testing for LGI1 antibodies in patients with unexplained neuropathic pain?

1
1 Answers

Mednet Member
Mednet Member
Neurology · University of Minnesota

I would strongly consider testing CASPR2 and LGI1 antibodies in any patient with unexplained, subacute or chronic "neuropathic-sounding" pain (e.g. described as hot/burning, stabbing, "pins-needles", etc) especially if: exacerbated by heat, experienced diffusely in a "non-length dependent" pattern (...

How do you manage problematic disinhibited behaviors in patients with neurocognitive disorders?

7
10 Answers

Mednet Member
Mednet Member
Psychiatry · McLean Hospital/Harvard Medical School

This requires a problem-centered approach. I suggest the following thought process. Analyse the root cause: Is it disinhibition? Unmet needs? Under/Overstimulating environment? Medication side effect? For disinhibition (frontal lobe dysfunction): I have had success with gabapentin and low-dose Depa...

How would you manage a CVST secondary to a traumatic brain injury with the presence of intracranial hemorrhage?

4
4 Answers

Mednet Member
Mednet Member
Neurology · ChristianaCare

When dealing with CVST after TBI, the mechanism of injury is not the same as a spontaneous CVST. There is often direct injury to the vein or the area overlying it. Given that these patients often have other traumatic injuries, and given the lack of clear evidence to support one therapy or another, I...

What patient factors most strongly influence your decision to start biologic agents in mild cognitive impairment?

1
1 Answers

Mednet Member
Mednet Member
Neurology · Mount Sinai Medical Center

1.Absence of need for anticoagulants ( this is exclusionary) 2. Absence of APOE e4 homozygosity (although we do treat e4 homozygotes, but with much greater precautionary measures - especially the dosing protocol) 3. High functional ability, and adherence to healthy lifestyle measures (exercise, die...

What is your approach to titration of sublingual cyclobenzaprine in your patients with fibromyalgia?

3 Answers

Mednet Member
Mednet Member
Rheumatology · The University of Michigan

Follow the FDA instructions: start at 2.8 mg sublingually at bedtime for 14 days, if tolerating, then increase to 5.6 mg nightly starting day 15 onwards. Ensure the mouth is not too dry as saliva is needed for it to fully dissolve, which could take 2-3 mins. This may be a concern in patients with SI...